Andrew Oxtoby
Board Member
Kalaris Therapeutics, Inc. (KLRS)Equibles does not estimate personal net worth.
Get an email with a short summary when Kalaris Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get KLRS alertsAbout Andrew Oxtoby
Andrew Oxtoby is recorded as Board Member and CEO at Kalaris Therapeutics, Inc. (KLRS). The newest filing on record that lists Andrew Oxtoby as Board Member and CEO at Kalaris Therapeutics, Inc. (KLRS) is dated April 24, 2026. Kalaris Therapeutics, Inc. reported in an 8-K filed March 18, 2025 that Andrew Oxtoby was appointed Chief Executive Officer and principal executive officer. Kalaris Therapeutics, Inc. reported in an 8-K filed March 18, 2025 that Andrew Oxtoby was appointed Chief Executive Officer, effective March 18, 2025. Kalaris Therapeutics, Inc. reported in an 8-K filed March 18, 2025 that Andrew Oxtoby was appointed Board, effective March 18, 2025. The proxy statement of Kalaris Therapeutics, Inc. reports total compensation of $2,569,115 for Andrew Oxtoby in fiscal 2025, including a base salary of $537,733. Disclosed compensation is on record for 2 fiscal years. Kalaris Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Kalaris Therapeutics, Inc. includes Diana M. Brainard (CEO and Board Member), Vikas Sinha (CEO), David Hallal (Chairman and Board Member) and 7 others.
“On the Closing Date, the Board appointed Andrew Oxtoby as the Combined Company's Chief Executive Officer and principal executive officer”
“On the Closing Date, the Board appointed Andrew Oxtoby as the Combined Company's Chief Executive Officer and principal executive officer”
Affiliation history
-
Current
Start not stated–present
Last confirmed April 24, 2026
-
Current
Start not stated–present
Last confirmed April 24, 2026
Company network
Leadership on record at Kalaris Therapeutics, Inc.
- Diana M. Brainard CEO, Board Member
- Vikas Sinha CEO
- David Hallal Chairman, Board Member
- Brett Hagen CFO
- Liisa Bayko CFO
- Matthew Gall CFO
- Amy Vandekop Chief Accounting Officer
- Anthony Adamis Board Member
- Derek Adams, Ph.D. Board Member
- Laurie Keating Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Kalaris Therapeutics, Inc. (KLRS) | President and Chief Executive Officer | $537,733 | $2,569,115 |
| 2024 | Kalaris Therapeutics, Inc. (KLRS) | Current President and Chief Executive Officer | $394,160 | $1,965,153 |